<?xml version="1.0" encoding="UTF-8"?>
<xml>
  <records>
    <record>
      <source-app name="Horizon">Horizon</source-app>
      <rec-number>1</rec-number>
      <foreign-keys>
        <key app="Horizon" db-id="fdi:010088923">1</key>
      </foreign-keys>
      <ref-type name="Journal Article">17</ref-type>
      <work-type>ACL : Articles dans des revues avec comité de lecture répertoriées par l'AERES</work-type>
      <contributors>
        <authors>
          <author>
            <style face="normal" font="default" size="100%">Bell, D.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Brown, G. W.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Oyibo, W. A.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Ouedraogo, S.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Tacheva, B.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Barbaud, E.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Kalk, A.</style>
          </author>
          <author>
            <style face="bold" font="default" size="100%">Ridde, Valéry</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Paul, E.</style>
          </author>
        </authors>
      </contributors>
      <titles>
        <title>COVAX - Time to reconsider the strategy and its target</title>
        <secondary-title>Health Policy Open</secondary-title>
      </titles>
      <pages>100096 [6 ]</pages>
      <dates>
        <year>2023</year>
      </dates>
      <call-num>fdi:010088923</call-num>
      <language>ENG</language>
      <periodical>
        <full-title>Health Policy Open</full-title>
      </periodical>
      <accession-num>ISI:001135964800001</accession-num>
      <electronic-resource-num>10.1016/j.hpopen.2023.100096</electronic-resource-num>
      <urls>
        <related-urls>
          <url>https://www.documentation.ird.fr/hor/fdi:010088923</url>
        </related-urls>
        <pdf-urls>
          <url>https://horizon.documentation.ird.fr/exl-doc/pleins_textes/2024-02/010088923.pdf</url>
        </pdf-urls>
      </urls>
      <volume>4</volume>
      <remote-database-provider>Horizon (IRD)</remote-database-provider>
      <abstract>COVAX, the international initiative supporting COVID-19 vaccination campaigns globally, is budgeted to be the costliest public health initiative in low- and middle-income countries, with over 16 billion US dollars already committed. While some claim that the target of vaccinating 70% of people worldwide is justified on equity grounds, we argue that this rationale is wrong for two reasons. First, mass COVID-19 vaccination campaigns do not meet standard public health requirements for clear expected benefit, based on costs, disease burden and intervention effectiveness. Second, it constitutes a diversion of resources from more cost-effective and impactful public health programmes, thus reducing health equity. We conclude that the COVAX initiative warrants urgent review.</abstract>
      <custom6>056 ; 052</custom6>
      <custom1>UR196</custom1>
      <custom7>Burkina Faso / République démocratique du Congo / Nigéria</custom7>
    </record>
  </records>
</xml>
